EYDENZELT (Celltrion Healthcare Australia Pty Ltd)
Product name
EYDENZELT
Date registered
Evaluation commenced
Decision date
Approval time
199 (255 working days)
Active ingredients
Aflibercept
Registration type
New biosimilar medicine
Indication
EYDENZELT 2 mg (aflibercept) is indicated in adults for the treatment of:
- Visual impairment due to myopic choroidal neovascularisation (myopic CNV).